We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Characterization of Proteoglycan Depletion in Femoroacetabular Impingement With T1ρ Magnetic Resonance Imaging (MRI)

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01578694
First Posted: April 17, 2012
Last Update Posted: May 11, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Ottawa Hospital Research Institute
  Purpose
Magnetic resonance imaging (MRI) is one of the best ways to image articular cartilage. One of the techniques which has shown great promise is the imaging technique called T1ρ (T1-rho). T1ρ is a modified pulse sequence from the standard T1 sequence used in the clinical MRI. Because the initial phases of arthritis occur at the molecular level, the main advantage of the T1ρ pulse sequence is that it is sensitive to proteoglycan. Proteoglycan is a molecule that is important to cartilage structure, and is lost as osteoarthritis develops. If we can show that this non-invasive tool can accurately assess cartilage damage and levels of proteoglycan, the clinical applications are numerous. The results can potentially help determine optimal surgical techniques and timing of surgical intervention to halt or slow the progression of arthritis, and will assist in the study of the effects of FAI and the success of the surgery performed to correct FAI.

Condition Intervention
Femoroacetabular Impingement Cartilage, Articular Hip Joint MRI Procedure: MRI

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Other
Official Title: Characterization of Proteoglycan Depletion in Femoroacetabular Impingement With T1ρ MRI

Further study details as provided by Ottawa Hospital Research Institute:

Primary Outcome Measures:
  • T1rho MRI [ Time Frame: Pre-op (within 6 weeks prior to surgery) ]

Enrollment: 26
Study Start Date: July 2007
Study Completion Date: December 2012
Primary Completion Date: December 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Patient Procedure: MRI
T1 rho MRI
Control Procedure: MRI
T1 rho MRI

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 40 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Subjects:

Number

  1. N=10
  2. From: Dr. Paul Beaule's Practice, Ottawa General Hospital, Ottawa, ON

Inclusion Criteria (must meet all criteria listed below) A) History and Physical Exam

  1. Intermittent Pain worse with activity
  2. Positive Impingement test (Pain with flexion, adduction and internal rotation of effected hip)

B) X-ray

1. No signs of OA on plain radiological films (i.e. no osteophytes, no loss of joint space) 3. Non-spherical femoral head

Exclusion Criteria:

  1. Previous Hip Surgeries (Pelvic Osteotomies)
  2. Previous Hip Trauma
  3. Hx of Pediatric Hip Pathology: Slipped Capital Femoral Epiphysis or Hip Dysplasia
  4. Over the age of 40 years
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01578694


Locations
Canada, Ontario
The Ottawa Hospital
Ottawa, Ontario, Canada, K1H 8L6
Sponsors and Collaborators
Ottawa Hospital Research Institute
Investigators
Principal Investigator: Paul E Beaule, MD, FRCSC University of Ottawa / The Ottawa Hospital